For TET1, overexpression has been reported in both MLL-rearranged leukemia and cytogenetically normal AML patients and was found to be correlated with a poor OS in the latter group, thus suggesting a pro-oncogenic role for TET1 in hematological cancers (161, 162). The gene discussed is TET1; the disease is hematopoietic and lymphoid cell neoplasm.